366 related articles for article (PubMed ID: 21987739)
1. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs.
Richardson JS; Abou MC; Tran KN; Kumar A; Sahai BM; Kobinger GP
J Infect Dis; 2011 Nov; 204 Suppl 3():S1032-42. PubMed ID: 21987739
[TBL] [Abstract][Full Text] [Related]
2. Airway delivery of an adenovirus-based Ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates.
Richardson JS; Pillet S; Bello AJ; Kobinger GP
J Virol; 2013 Apr; 87(7):3668-77. PubMed ID: 23302894
[TBL] [Abstract][Full Text] [Related]
3. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.
Kobinger GP; Feldmann H; Zhi Y; Schumer G; Gao G; Feldmann F; Jones S; Wilson JM
Virology; 2006 Mar; 346(2):394-401. PubMed ID: 16356525
[TBL] [Abstract][Full Text] [Related]
4. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice.
Croyle MA; Patel A; Tran KN; Gray M; Zhang Y; Strong JE; Feldmann H; Kobinger GP
PLoS One; 2008; 3(10):e3548. PubMed ID: 18958172
[TBL] [Abstract][Full Text] [Related]
5. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals.
Wong G; Richardson JS; Cutts T; Qiu X; Kobinger GP
Antiviral Res; 2015 Apr; 116():17-9. PubMed ID: 25596432
[TBL] [Abstract][Full Text] [Related]
6. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
[TBL] [Abstract][Full Text] [Related]
7. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.
Bukreyev A; Yang L; Zaki SR; Shieh WJ; Rollin PE; Murphy BR; Collins PL; Sanchez A
J Virol; 2006 Mar; 80(5):2267-79. PubMed ID: 16474134
[TBL] [Abstract][Full Text] [Related]
8. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice.
Patel A; Zhang Y; Croyle M; Tran K; Gray M; Strong J; Feldmann H; Wilson JM; Kobinger GP
J Infect Dis; 2007 Nov; 196 Suppl 2():S413-20. PubMed ID: 17940978
[TBL] [Abstract][Full Text] [Related]
9. Generation of an adenoviral vaccine vector based on simian adenovirus 21.
Roy S; Zhi Y; Kobinger GP; Figueredo J; Calcedo R; Miller JR; Feldmann H; Wilson JM
J Gen Virol; 2006 Sep; 87(Pt 9):2477-2485. PubMed ID: 16894185
[TBL] [Abstract][Full Text] [Related]
10. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine.
Richardson JS; Yao MK; Tran KN; Croyle MA; Strong JE; Feldmann H; Kobinger GP
PLoS One; 2009; 4(4):e5308. PubMed ID: 19390586
[TBL] [Abstract][Full Text] [Related]
11. A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection.
Choi JH; Jonsson-Schmunk K; Qiu X; Shedlock DJ; Strong J; Xu JX; Michie KL; Audet J; Fernando L; Myers MJ; Weiner D; Bajrovic I; Tran LQ; Wong G; Bello A; Kobinger GP; Schafer SC; Croyle MA
Mol Pharm; 2015 Aug; 12(8):2712-31. PubMed ID: 25363619
[TBL] [Abstract][Full Text] [Related]
12. A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.
Choi JH; Schafer SC; Zhang L; Kobinger GP; Juelich T; Freiberg AN; Croyle MA
Mol Pharm; 2012 Jan; 9(1):156-67. PubMed ID: 22149096
[TBL] [Abstract][Full Text] [Related]
13. Development of a preventive vaccine for Ebola virus infection in primates.
Sullivan NJ; Sanchez A; Rollin PE; Yang ZY; Nabel GJ
Nature; 2000 Nov; 408(6812):605-9. PubMed ID: 11117750
[TBL] [Abstract][Full Text] [Related]
14. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
[TBL] [Abstract][Full Text] [Related]
15. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.
Tsuda Y; Caposio P; Parkins CJ; Botto S; Messaoudi I; Cicin-Sain L; Feldmann H; Jarvis MA
PLoS Negl Trop Dis; 2011 Aug; 5(8):e1275. PubMed ID: 21858240
[TBL] [Abstract][Full Text] [Related]
16. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
17. Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine.
Choi JH; Schafer SC; Freiberg AN; Croyle MA
Mol Pharm; 2015 Aug; 12(8):2697-711. PubMed ID: 25549696
[TBL] [Abstract][Full Text] [Related]
18. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.
Ewer K; Rampling T; Venkatraman N; Bowyer G; Wright D; Lambe T; Imoukhuede EB; Payne R; Fehling SK; Strecker T; Biedenkopf N; Krähling V; Tully CM; Edwards NJ; Bentley EM; Samuel D; Labbé G; Jin J; Gibani M; Minhinnick A; Wilkie M; Poulton I; Lella N; Roberts R; Hartnell F; Bliss C; Sierra-Davidson K; Powlson J; Berrie E; Tedder R; Roman F; De Ryck I; Nicosia A; Sullivan NJ; Stanley DA; Mbaya OT; Ledgerwood JE; Schwartz RM; Siani L; Colloca S; Folgori A; Di Marco S; Cortese R; Wright E; Becker S; Graham BS; Koup RA; Levine MM; Volkmann A; Chaplin P; Pollard AJ; Draper SJ; Ballou WR; Lawrie A; Gilbert SC; Hill AV
N Engl J Med; 2016 Apr; 374(17):1635-46. PubMed ID: 25629663
[TBL] [Abstract][Full Text] [Related]
19. Correlates of vaccine-induced protective immunity against Ebola virus disease.
Medaglini D; Santoro F; Siegrist CA
Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831
[TBL] [Abstract][Full Text] [Related]
20. Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.
Choi JH; Schafer SC; Zhang L; Juelich T; Freiberg AN; Croyle MA
Mol Pharm; 2013 Sep; 10(9):3342-55. PubMed ID: 23915419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
